Onyx Biotec Limited (NSE:ONYX)
36.60
-1.35 (-3.56%)
At close: Jun 17, 2026
Onyx Biotec Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 694.69 | 619.51 | 537.49 | 394.82 | 448.61 |
Other Revenue | - | - | - | 0.1 | - |
| 694.69 | 619.51 | 537.49 | 394.92 | 448.61 | |
Revenue Growth (YoY) | 12.13% | 15.26% | 36.10% | -11.97% | - |
Cost of Revenue | 516.53 | 400.97 | 367.28 | 221.33 | 279.1 |
Gross Profit | 178.17 | 218.55 | 170.21 | 173.59 | 169.51 |
Selling, General & Admin | 86.07 | 86.63 | 59.57 | 105.03 | 86.56 |
Other Operating Expenses | 58.13 | 28.21 | 26.96 | 23.1 | 25.69 |
Operating Expenses | 174.71 | 145.32 | 105.21 | 143.05 | 126.72 |
Operating Income | 3.45 | 73.23 | 65.01 | 30.54 | 42.79 |
Interest Expense | -12.11 | -19.93 | -21.07 | -5.65 | -5.15 |
Interest & Investment Income | - | 1.73 | 0.75 | 0.65 | 0.1 |
Currency Exchange Gain (Loss) | - | - | - | -0.01 | -0 |
Other Non Operating Income (Expenses) | 4.45 | 0.21 | 0.21 | 0.01 | 0.26 |
EBT Excluding Unusual Items | -4.22 | 55.24 | 44.9 | 25.54 | 38 |
Gain (Loss) on Sale of Assets | - | 9.54 | - | -0.07 | -0.05 |
Pretax Income | -4.22 | 64.78 | 44.9 | 25.47 | 37.95 |
Income Tax Expense | -2.07 | 15.24 | 8.55 | 7.02 | 4.42 |
Net Income | -2.14 | 49.54 | 36.35 | 18.45 | 33.53 |
Net Income to Common | -2.14 | 49.54 | 36.35 | 18.45 | 33.53 |
Net Income Growth | - | 36.31% | 97.04% | -44.98% | - |
Shares Outstanding (Basic) | 18 | 15 | 12 | 12 | 12 |
Shares Outstanding (Diluted) | 18 | 15 | 12 | 12 | 12 |
Shares Change (YoY) | 19.26% | 25.51% | 1.13% | - | - |
EPS (Basic) | -0.12 | 3.31 | 3.05 | 1.56 | 2.84 |
EPS (Diluted) | -0.12 | 3.31 | 3.05 | 1.56 | 2.84 |
EPS Growth | - | 8.60% | 95.20% | -45.07% | - |
Free Cash Flow | -64.81 | 3.62 | -17.07 | -165.01 | -53 |
Free Cash Flow Per Share | -3.63 | 0.24 | -1.43 | -13.98 | -4.49 |
Gross Margin | 25.65% | 35.28% | 31.67% | 43.95% | 37.79% |
Operating Margin | 0.50% | 11.82% | 12.09% | 7.73% | 9.54% |
Profit Margin | -0.31% | 8.00% | 6.76% | 4.67% | 7.47% |
Free Cash Flow Margin | -9.33% | 0.58% | -3.17% | -41.78% | -11.82% |
EBITDA | 33.97 | 103.7 | 83.68 | 45.45 | 57.27 |
EBITDA Margin | 4.89% | 16.74% | 15.57% | 11.51% | 12.77% |
D&A For EBITDA | 30.52 | 30.47 | 18.67 | 14.91 | 14.48 |
EBIT | 3.45 | 73.23 | 65.01 | 30.54 | 42.79 |
EBIT Margin | 0.50% | 11.82% | 12.09% | 7.73% | 9.54% |
Effective Tax Rate | - | 23.52% | 19.05% | 27.57% | 11.66% |
Revenue as Reported | 699.14 | 631.19 | 538.74 | 396.17 | 449.81 |
Advertising Expenses | - | 0.06 | 0.06 | 0.09 | 0.03 |